AcelRx Pharmaceuticals In... (ACRX)
NASDAQ: ACRX
· Real-Time Price · USD
0.86
0.06 (7.50%)
At close: Jan 09, 2024, 10:00 PM
AcelRx Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -3.49M | -2.59M | 876K | -3.35M | n/a | -4.52M | -1.36M | -4.37M | -8.15M | -7.48M | -6.75M | 70.66M | -8.67M | -7.92M | -8.38M | -9.85M | -8.96M |
Depreciation & Amortization | n/a | n/a | -432K | -121K | n/a | n/a | n/a | 49K | 262K | 342K | 424K | 461K | 420K | 461K | 483K | 579K | 450K |
Stock-Based Compensation | 166K | 196K | -429K | 234K | n/a | 311K | 378K | 471K | 569K | 652K | 701K | 753K | 783K | 1.13M | 1.22M | 1.17M | 1.09M |
Other Working Capital | n/a | n/a | 237K | 524K | n/a | -226K | 226K | -1.05M | 591K | -204K | 744K | -1.02M | -1.21M | -1.43M | 3.19M | -225K | -1.63M |
Other Non-Cash Items | 375K | -1.07M | 663K | -753K | n/a | -9K | -1.79M | -708K | 1.29M | 869K | 43K | -79.61M | -537K | -766K | -437K | -236K | -1.06M |
Deferred Income Tax | n/a | n/a | -1.23M | n/a | n/a | n/a | n/a | 1.23M | n/a | n/a | n/a | n/a | n/a | 810K | n/a | n/a | n/a |
Change in Working Capital | n/a | n/a | 1.41M | 1.06M | n/a | -132K | -193K | -2M | 785K | 208K | 344K | -1.02M | -926K | -1.72M | 3.17M | -11K | -1.23M |
Operating Cash Flow | -2.95M | -3.47M | 860K | -2.94M | n/a | -3.95M | -2.96M | -5.33M | -5.25M | -5.41M | -5.24M | -8.75M | -8.93M | -8M | -3.94M | -8.35M | -9.71M |
Capital Expenditures | n/a | n/a | 100K | n/a | n/a | n/a | n/a | n/a | -100K | -48K | -158K | -69K | -89K | -28K | -184K | -1.59M | -24K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.69M | n/a | n/a | -1.16M | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | -4.98M | n/a | n/a | -3.65M | n/a | n/a | n/a | -492K | n/a | -1.19M | -6.17M | -16.59M | -15.67M | -13.76M | -24.44M |
Sales Maturities Of Investments | n/a | n/a | 8.26M | 600K | n/a | n/a | n/a | n/a | 500K | 3.2M | 4.6M | 10.97M | 27.6M | 13M | 9.2M | 17.74M | 7.04M |
Other Investing Acitivies | n/a | n/a | -2.72M | n/a | n/a | n/a | n/a | 2.72M | n/a | 1.69M | n/a | -531K | n/a | -821K | n/a | n/a | n/a |
Investing Cash Flow | n/a | n/a | 658K | 600K | n/a | -3.65M | n/a | 2.72M | 400K | 2.66M | 4.44M | 9.17M | 20.18M | -4.44M | -6.65M | 2.39M | -17.43M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | 22K | 3K | n/a | n/a | n/a | n/a | -22K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | -22K | n/a | n/a | n/a | n/a | n/a | -22K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 4.35M | -5K | 13.9M | 30K | n/a | n/a | 8.94M | -3.33M | -2.05M | 5.3M | -1.64M | -2.08M | -2.08M | 11.84M | -2.46M | -2.08M | 34.22M |
Financial Cash Flow | 4.35M | -5K | 8.51M | 30K | n/a | -68K | 8.94M | -3.33M | -2.07M | 5.3M | -1.64M | -2.08M | -2.08M | 11.84M | -2.46M | -2.08M | 34.22M |
Net Cash Flow | 1.4M | -3.48M | -4.53M | -2.31M | n/a | n/a | 5.98M | -5.94M | -6.92M | 2.54M | -2.43M | -1.66M | 9.16M | -608K | -13.06M | -8.04M | 7.09M |
Free Cash Flow | -2.95M | -3.47M | 960K | -2.94M | n/a | -3.95M | -2.96M | -5.33M | -5.35M | -5.46M | -5.4M | -8.81M | -9.02M | -8.03M | -4.13M | -9.94M | -9.73M |